SCHEMBL525554

SCHEMBL525554

CCC1c2nncn2-c2cnc(NC(C)c3ccc(N4CCNCC4)cc3)nc2N1C1CCCC1.CCC1c2nncn2-c2cnc(NC(C)c3ccccc3)nc2N1c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 4/20 0.52
RPS6KA6 Q9UK32 1/20 0.38
PLK1 P53350 8/20 0.35
IDH1 O75874 6/20 0.35
CDK4 P11802 3/20 0.35
CCND1 P24385 2/20 0.35
CCND2 P30279 1/20 0.35
CCND3 P30281 1/20 0.35
PLK3 Q9H4B4 3/20 0.34
PLK2 Q9NYY3 3/20 0.34
MARK3 P27448 1/20 0.34
MARK4 Q96L34 1/20 0.34
CDK6 Q00534 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
KCNH2 Q12809 1/20 0.33
FGFR1 P11362 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL523785 0.93 BRD4 (0.54) BRD4RPS6KA6PLK1IDH1CDK4
SCHEMBL523786 0.93 BRD4 (0.54) BRD4RPS6KA6PLK1IDH1CDK4
SCHEMBL20815329 0.93 BRD4 (0.54) BRD4RPS6KA6PLK1IDH1CDK4
SCHEMBL523440 0.93 BRD4 (0.54) BRD4RPS6KA6PLK1IDH1CDK4
SCHEMBL523203 0.87 BRD4 (0.66) BRD4PLK1IDH1PLK3PLK2
SCHEMBL524305 0.87 BRD4 (0.66) BRD4PLK1IDH1PLK3PLK2
SCHEMBL524306 0.87 BRD4 (0.66) BRD4PLK1IDH1PLK3PLK2
SCHEMBL524048 0.85 BRD4 (0.55) BRD4RPS6KA6PLK1PLK3PLK2
SCHEMBL20815288 0.85 BRD4 (0.55) BRD4RPS6KA6PLK1PLK3PLK2
SCHEMBL522804 0.85 BRD4 (0.55) BRD4RPS6KA6PLK1PLK3PLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8278297-B2 Protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-02 US disclosed
US-20120028966-A1 PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028966-A1 PROTEIN KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 BRD4 1038/4885RPS6KA6 105/4885PLK1 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.